Topical Insulin Mucoadhesive Composition for Diabetic Ulcers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for skin ailments such as diabetic ulcers are ineffective for many patients due to underlying biological changes that hinder tissue repair, leading to significant health issues and limited treatment options.
Innovation Solution
Topical compositions comprising insulin and a mucoadhesive polymer carrier, which includes at least two polysaccharide polymers, are developed for treating skin ailments like diabetic ulcers, with methods involving topical administration and optional additional treatments like antibiotics or wound care.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments such as debridement, negative pressure therapy, and offloading orthotics are used, then wound closure can be achieved in some patients, but treatment effectiveness is limited and many patients experience resistance due to underlying biological changes
Solution Approach 1:
The patent changes the biochemical parameters of the wound environment by applying topical insulin, which directly addresses the underlying biological changes in diabetic wound patients. This shifts the treatment approach from mechanical/physical methods to biochemical modulation, improving treatment effectiveness for patients with diabetic ulcers who have specific metabolic abnormalities affecting healing.
Solution Approach 2:
The patent introduces insulin as an intermediary substance that mediates between the wound healing process and the patient's diabetic condition. By applying insulin topically, it serves as a targeted intervention that addresses the specific biological barrier (hyperglycemia-induced healing impairment) without requiring systemic treatment changes.
2Productivity
If conventional wound treatments are applied, then some wound closure is achieved, but the treatments are ineffective for many others due to underlying biological changes
Solution Approach 1:
The patent directly modifies the biochemical parameters affecting wound healing by applying insulin topically. This addresses the root cause (hyperglycemia) rather than just treating symptoms, leading to more consistent and reliable wound closure across different patients with diabetic ulcers.
Solution Approach 2:
The topical insulin formulation allows the wound to heal by directly addressing the biological barrier at the wound site. The insulin applied topically is absorbed by the wound tissue and acts locally to improve healing, enabling the wound healing process to proceed effectively despite the patient's diabetic condition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions enhance wound healing by improving tissue repair and managing blood sugar levels, potentially reducing complications and promoting faster healing.
Implementation Method 1
a mucoadhesive polymer carrier comprising at least two polysaccharide polymers
Data Source
AI summary
The present disclosure is concerned with compositions comprising insulin and a pharmaceutically acceptable topical carrier. The present disclosure is also concerned with methods of using these compositions for the treatment of a skin ailment such as a diabetic ulcer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.